Mass General Brigham researchers used long-term data and a blood test for the biomarker pTau217 to identify the earliest signs of Alzheimer’s disease in cognitively healthy adults.

Amyloid-beta-targeted monoclonal antibodies probably resulted in little to no difference in cognitive function or in dementia severity.

A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...

Anti-amyloid drugs likely provide no "clinically meaningful" effects for people with Alzheimer's, the authors concluded.

Anti-amyloid drugs may not have a clinically meaningful effect in the treatment of Alzheimer's disease, a new review says. So ...

A new study​ finds that a simple blood test could predict Alzheimer's disease long before symptoms appear.

Plasma pTau217 may detect initial buildup of AD-related brain changes before they can be detected by current ‘gold standard’ ...

Currently, PET (positron emission tomography) brain scans are often used to spot these signs – but perhaps pTau217 blood ...

Most neurons that die in Alzheimer’s disease do not simply starve or get smothered by amyloid plaques. According to a study ...

Can weight-loss drugs like semaglutide prevent Alzheimer's? New research reveals GLP-1 drugs reduce amyloid and tau proteins ...

The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein ...